Navigation Links
Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology

BOSTON--(BUSINESS WIRE)--May 1, 2007 - Genentech, Inc. (NYSE:DNA) and Biogen Idec, Inc. (Nasdaq:BIIB) announced that positive data from a Phase II clinical study of Rituxan(R) (rituximab) in patients with relapsing-remitting multiple sclerosis (RRMS) were presented today at the American Academy of Neurology annual meeting held in Boston. Rituxan is a therapeutic antibody that targets and selectively depletes CD20-positive B-cells.

"There remains a great need for safe and effective treatments for patients with RRMS," said Stephen Hauser, MD, Professor and Chair, Department of Neurology, University of California, San Francisco. "These Phase II results are very encouraging and suggest B-cells play a key role in MS. They also lend support to the concept that selective targeting of B-cells may be an important approach to treating this debilitating disease."

In this Phase II double-blind, placebo-controlled study that evaluated the safety and efficacy of Rituxan in adult patients with RRMS, 104 patients were randomized to receive either a single treatment course of Rituxan (two infusions separated by two weeks) or placebo. The primary endpoint was defined as the total number of gadolinium-enhancing T1 lesions at weeks 12, 16, 20 and 24, as measured by serial MRI scans of the brain. The total number of gadolinium lesions at weeks 12, 16, 20 and 24 was statistically significantly reduced in patients receiving Rituxan compared to those receiving placebo (p less than 0.0001). At week 24, the total cumulative mean number of gadolinium lesions per patient was reduced by 91 percent, to 0.5 in the Rituxan-treated group from 5.5 in the placebo group.

In addition, the proportion of patients with relapses over 24 weeks in the Rituxan-treated arm was 14.5 percent compared to 34.3 percent in the placebo arm (58 percent relative reduction) (p = 0.0238).

With the exception of infusion associated adverse events,
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:5/20/2013)... 2013   National Community Pharmacists Association (NCPA) ... MBA issued the following statement today regarding a ... D "preferred pharmacy" drug plans , which often ... lowest advertised co-payments: (Logo:  http://photos.prnewswire.com/prnh/20100106/DC33253LOGO ) ... MedPAC , 16 U.S. Senators and ...
(Date:5/20/2013)... 20, 2013  Hill-Rom Holdings, Inc. (NYSE: ... presentation at the 38 th Annual Deutsche Bank ... on May 30, 2013, at 1:30 p.m. EDT. ... are invited to listen to the live discussion via ... it directly at http://www.media-server.com/m/p/f7bj3q84 . A recorded replay ...
(Date:5/20/2013)... May 20, 2013 Sequent Medical, Inc. announced ... SL ("Single Layer") family of WEB ® Aneurysm ... these new models in select neurovascular centers in Europe.  ... navigability that will enable physicians to treat a broader ... The SL configurations are made possible by further advancement ...
Breaking Medicine Technology:Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 2Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 3Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 4Sequent Medical, Inc. Launches New SL Family of WEB Aneurysm Embolization Devices 2
... of Valecor Platinum(TM) Coronary Stent System Indicate, ... Market-Leading Bare Stent, BURLINGTON, Mass., Oct. ... Eric Ryan, M.D., Chairman & CEO of ... studies for CorNova,s Valecor,Platinum(TM) Coronary Stent System ...
... a,biopharmaceutical company focused on the development of novel,anti-inflammatory ... I,tolerance study of MRX-4 in 16 patients suffering ... blind clinical trial is the,first of two modules ... in,AR. MRX-4 is nasally administered as a single ...
Cached Medicine Technology:CorNova Preclinical Results of Valecor Platinum(TM) Coronary Stent Studies Presented at TCT 2007 Conference 2Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis 2
(Date:5/20/2013)... 20, 2013 Fastcare Miami Beach clinic ... (UTI) within its first symptoms, as if not treated, it ... more serious infection. Although a urinary tract infection in itself ... to serious kidney infection called pyelonephritis. Women seem to have ... up to the same percentage as women after the age ...
(Date:5/20/2013)... In order to prepare for the long ... from DrSmartphoneMD launched an article series to raise awareness about ... series launched with the precautions that need to be ... program are not one of the 3.5 million cases of ... 90% of all skin cancer cases are associated with exposure ...
(Date:5/20/2013)... May 20, 2013 Eben ... to the public creating a frenzy among business ... this elite business training. WealthSpringMarketing.com's Tiffany Hendricks has ... as an exclusive bonus. , "Eben Pagan is ... business training to individuals serious about success," reports ...
(Date:5/20/2013)... 20, 2013 Parker Waichman LLP, a ... victims injured by defective drugs, has filed a lawsuit ... that use of the diabetes drug medication Actos ... on April 30, 2013, in the U.S. District Court ... where it is one of thousands of cases pending ...
(Date:5/20/2013)... 2013 Leading facial plastic surgeon and ENT ... a “Top Doc” in the field of Otolaryngology in the ... The Palm Beacher magazine, one of Palm Beach County’s leading ... the May/June 2013 issue, including 70 of the very best ... events, things to do, health and fitness, people to watch, ...
Breaking Medicine News(10 mins):Health News:Fastcare Advises on How to Prevent a UTI 2Health News:Combat Skin Cancer In Summer Months 2Health News:Eben Pagan's Accelerate: Review and Bonus Released By WealthSpringMarketing.com 2Health News:Taking Actos for Two Years Caused Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP on Behalf of South Dakota Man 2Health News:Dr. Schwartz Named “Top Doc” by The Palm Beacher Magazine 2
... working with an international team of health and ... to provide long-term weather forecasts to medical officials ... The forecasts will enable local health providers to ... disease, which is correlated with dry and dusty ...
... 19 Medipacs, Inc., a Tucson based drug,delivery device company ... Invest Southwest Capital Conference to be held in Scottsdale,AZ on ... One of only 12 companies to present at ... of high-tech fields. "Generally,speaking, (the businesses) have to be highly ...
... consumers filed a proposed,nationwide class-action lawsuit earlier this week ... BAY), alleging the pharmaceutical giant,skirted FDA requirements in marketing ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080317/AQM144LOGO ) , ... markets two of its over-the-counter products --,Bayer Aspirin with ...
... A. Hoke,has joined the Sisters of Charity Health System ... for the Cleveland-,based organization and its 20 health and ... announcement was made by Sisters of Charity Health System,President ... "We are pleased to ...
... Nov. 19 Healthcare Management Systems,Inc.(R) (HMS) presented the 4th Annual ... the healthcare field. The awards were,presented Friday, October 17, during the ... Awards were presented to the following nominees: , ... Respiratory Care Center, Inc., Mt.,Vernon, Ky. , ...
... 19 Have you ever asked yourself, "What in the world ... safe to give your puppy a leftover turkey drumstick - or ... , , To address these and ... (AVMA) today launched a new podcast series, "Chew on This," dedicated ...
Cached Medicine News:Health News:UCAR weather forecasts aim to reduce African meningitis epidemics 2Health News:UCAR weather forecasts aim to reduce African meningitis epidemics 3Health News:Medipacs Chosen to Present at Invest Southwest Capital Conference 2Health News:Hagens Berman Files Class Action Against Bayer Healthcare Over Misleading Marketing Campaign 2Health News:Hagens Berman Files Class Action Against Bayer Healthcare Over Misleading Marketing Campaign 3Health News:Wendy Hoke Joins the Sisters of Charity Health System as Communications Officer 2Health News:Wendy Hoke Joins the Sisters of Charity Health System as Communications Officer 3Health News:HMS Presents 4th Annual Heroes of Healthcare Awards 2Health News:HMS Presents 4th Annual Heroes of Healthcare Awards 3Health News:AVMA Launches 'Chew on This' Podcast Series on Food Safety 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: